Intravenous diclofenac as prophylactic treatment for verteporfin-associated low back pain

European Journal of Ophthalmology

Volumn 18, Issue 5, 2008, Pages 805-808

  Theelen, Thomas ^a   Hoyng, C B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adverse effects; Diclofenac; Low back pain; Verteporfin

Indexed keywords

DICLOFENAC; VERTEPORFIN;

ADULT; AGED; ANALGESIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BURN; CONSTIPATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; HAIR LOSS; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; INJECTION SITE PAIN; KIDNEY PAIN; LOW BACK PAIN; MAJOR CLINICAL STUDY; NAUSEA; PAIN ASSESSMENT; PHLEBITIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROPHYLAXIS; RASH; SUBRETINAL NEOVASCULARIZATION; SYNCOPE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT OUTCOME;

EID: 54349115174     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800523     Document Type: Article

References (15)

1. Muller-Velten R, Michels S, Schmidt-Erfurth U, Laqua H. Photodynamic therapy: extended indication. Ophthalmologe 2003; 100: 384-90.
2. Brown GC, Brown MM, Brown HG, Kindermann S, Sharma S. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology 2007; 114: 1170-8.
3. Costa RA, Jorge R, Calucci D, Melo LAS, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVE study). Graefes Arch Clin Exp Ophthalmol 2007; 245: 1273-80.
4. Brown MM, Brown GC, Brown HG, Peet J. A value-based medicine analysis of ranibizumab for the treatment of sub-foveal neovascular macular degeneration. Ophthalmology 2008; 115: 1039-45.
5. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124: 1532-42.
6. Schnurrbusch UEK, Jochmann C, Einbock W, Wolf S. Complications after photodynamic therapy. Arch Ophthalmol 2005; 123: 1347-50.
7. Pece A, Vadala M, Manzi R, Calori G. Back pain after photodynamic therapy with verteporfin. Am J Ophthalmol 2006; 141: 593-4.
8. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005; 25: 119-34.
9. Dreiser RL, Marty M, Ionescu E, Gold M, Liu JH. Relief of acute low back pain with diclofenac-K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo-controlled clinical trial. Int J Clin Pharmacol Ther 2003; 41: 375-85.
10. Spaide RF, Maranan L. Neutrophil margination as a possible mechanism for verteporfin infusion-associated pain. Am J Ophthalmol 2003; 135: 549-50.
11. Scieszka JF, Maggiora LL, Wright SD, Cho MJ. Role of complements C3 and C5 in the phagocytosis of liposomes by human neutrophils. Pharm Res 1991; 8: 65-9.
12. Suzuki K, Nakazato K, Takama M. Adhesion molecule and cytokines of hypertensive rat arteries. Acta Histochem Cytochem 1998; 31: 177-83.
13. Perianin A, Gougerot-Pocidalo MA, Giroud JP, Hakim J. Diclofenac sodium, a negative chemokinetic factor for neutrophil locomotion. Biochem Pharmacol 1985; 34: 3433-8.
14. Takeda AL, Colquitt J, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol 2007; 91: 1177-82.
15. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007; 114: 1179-85.